Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Enveric Biosciences, Inc.

Ticker
ENVB
Sector
Industry
Report date
November 14, 2026
Valye AI Score

86

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Enveric's progress in advancing its lead candidate EB-003 toward clinical testing, financial activities to support pipeline development, and positive preclinical data.

Recent developments:
  • Enveric Biosciences moved its lead neuroplastogenic candidate EB-003 closer to clinical testing, indicating advancement in preclinical development stages [N1].
  • The company reported a $1 million loss in Q1 while advancing EB-003 in preclinical studies, reflecting ongoing R&D investment [N2].
  • Enveric closed a $13.9 million private placement to advance its neuroplastogen pipeline, providing capital for development activities [N4].
  • Positive assay data for EB-003 showed dual 5-HTA pathway engagement, supporting its mechanism of action [N6].
  • Enveric announced plans to release an investor presentation outlining its pipeline and development strategy [N5].
Overview

Enveric Biosciences, Inc. focuses on developing novel small-molecule therapeutics that promote neuroplasticity without hallucinogenic effects, addressing unmet needs in mental health. Its lead drug candidate, EB-003, is a derivative of DMT designed to selectively engage serotonin receptors 5-HT 2A and 5-HT 1B, aiming for fast-acting antidepressant and anxiolytic effects. The company is advancing EB-003 through preclinical studies with plans for IND filings and clinical trials. Enveric also maintains a broad intellectual property portfolio including 19 active patent families related to psychedelic-inspired compounds and cannabinoid conjugates. The company has a scientific advisory board comprising experts in psychiatry and clinical research. Financially, Enveric reported a net loss and maintains strong liquidity as of the latest quarterly filing.

Executive summary

Enveric Biosciences, Inc. is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders, with a lead candidate EB-003 in preclinical development targeting depression and neuropsychiatric conditions. The company holds extensive intellectual property portfolios and has reported a net loss of $2.55 million for the quarter ending September 30, 2026, with strong liquidity ratios. Recent developments include advancing EB-003 toward clinical testing and securing financing to support pipeline progression. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for ENVB

Bull case model:

Enveric's lead candidate EB-003 has advanced through preclinical toxicology studies and is positioned to enter IND-enabling studies, moving closer to clinical testing. The company has secured financing through a $13.9 million private placement to support pipeline advancement. Its broad patent portfolio and proprietary Psybrary™ library provide a foundation for multiple drug candidates targeting mental health disorders. Positive assay data demonstrating dual 5-HTA pathway engagement supports the scientific rationale for EB-003. The assembly of a scientific advisory board with leading clinical experts enhances the company's development and regulatory strategy.

Bear case model:

Enveric is currently in preclinical stages with no approved products, facing inherent risks of clinical development including regulatory approvals and demonstration of safety and efficacy. The company reported a net loss and relies on external financing to fund operations and pipeline progression. The competitive landscape for psychiatric and neurological therapeutics is intense, with alternative treatments and emerging technologies. The scientific advisory board members have limited availability due to commitments elsewhere, which may impact advisory support. Intellectual property challenges or failure to advance clinical programs could adversely affect the company's prospects.

Moat:

Enveric's moat is anchored in its proprietary drug discovery platform and extensive intellectual property portfolio comprising 19 active patent families covering psychedelic-inspired compounds and cannabinoid conjugates. The company's acquisition of MagicMed and access to the Psybrary™ library with over a million potential molecular structures synthesized and screened enhances its pipeline breadth. Its lead candidate EB-003 is a novel compound with a unique mechanism targeting dual serotonin receptors, potentially differentiating it from existing treatments. The involvement of a scientific advisory board with recognized experts further supports its development capabilities. These factors collectively contribute to barriers against competitors in the neuroplastogenic therapeutics space.

Risks overview
Risks summary
The primary risks involve clinical development uncertainties, financial sustainability, and competitive pressures in the neuropsychiatric therapeutics market.
Risks details:

• Clinical Development Risk: EB-003 and other candidates are in preclinical stages with inherent uncertainties in safety, efficacy, and regulatory approval processes.
• Financial Risk: The company reported net losses and depends on external financing to support ongoing research and development activities.
• Competitive Risk: The psychiatric and neurological disorder treatment markets are competitive with multiple alternative therapies and emerging technologies.
• Intellectual Property Risk: Challenges in protecting or enforcing patents could impact the company's competitive position and ability to commercialize products.
• Advisory Board Availability: Scientific advisors have commitments to other entities, potentially limiting their availability and focus on Enveric's programs.

FINAL FORECAST FOR ENVB

Final take one line
Enveric Biosciences has high visibility into its neuroplastogenic drug development pipeline with active preclinical progress and strong intellectual property, supported by recent financing and expert advisory.
Final take 12 to 24 month view

Business trends: Advancement of EB-003 through preclinical and IND-enabling studies, expansion of neuroplastogen pipeline, and ongoing patent portfolio development.
Execution milestones: Completion of IND filings, initiation of first-in-human clinical trials, and securing strategic partnerships or licensing agreements.
Key risks: Clinical development uncertainties, financial sustainability challenges, competitive pressures, and intellectual property protection risks.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

86
LLM visibility overview
LLM Visibility known facts
  • Enveric Biosciences, Inc. is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics targeting psychiatric and neurological disorders [S1].
  • The company leverages a differentiated drug discovery platform and a growing library of patent-protected chemical structures to advance novel compounds designed to promote neuroplasticity without hallucinogenic effects [S1].
  • Its lead candidate, EB-003, is a novel derivative of N,N-Dimethyltryptamine (DMT) designed to selectively engage both 5-HT 2A and 5-HT 1B receptors, aiming to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience [S1].
  • EB-003 is currently in preclinical development, having completed short-term dose-range finding toxicology studies and is advancing into IND-enabling, GLP-compliant safety pharmacology, ADMET, and longer-term toxicology studies [S1].
  • The company plans to initiate first-in-human studies to assess safety and tolerability including non-hallucinogenic properties, followed by clinical trials targeting depression and other neuropsychiatric disorders [S1].
  • Enveric has a pipeline expansion program called EVM401 Series intended to broaden its pipeline with additional non-hallucinogenic molecules targeting addiction and neuropsychiatric disorders, though the primary focus remains on EB-003 [S1].
  • The company acquired MagicMed Industries Inc. in 2021, gaining access to the Psybrary™ proprietary library, which includes 20 patent families covering about a million potential molecular structures, with over one thousand synthesized and hundreds screened for receptor binding and activity [S1].
  • Enveric owns rights to 19 active patent families related to phenylalkylamine and indolethylamine derivatives, represented by 24 issued US patents and 59 pending US and international patent applications for treatment of mental disorders including depression, anxiety, and addiction [S1].
  • The company also holds rights to cannabinoid-related patent families licensed to third parties for treatment of radiation dermatitis and pain/joint disease, with patents expiring as late as 2040 [S1].
  • Enveric has established a scientific advisory board with recognized experts in psychiatry and clinical research to guide its development programs [S1].
  • Financial snapshot as of 2026-09-30 shows cash and equivalents of $2.84 million, current assets of $6.25 million, current liabilities of $0.64 million, resulting in a current ratio of 9.7 and a cash ratio of 4.54, indicating strong liquidity [S2].
  • The company reported a net loss of $2.55 million for the quarter ending 2026-09-30 and basic and diluted EPS of -$0.57 [S2].
  • Recent news highlights include advancing EB-003 closer to clinical testing, reporting a $1 million loss in Q1 while progressing preclinical studies, closing a $13.9 million private placement to advance the neuroplastogen pipeline, and positive assay data showing dual 5-HTA pathway engagement [N1][N2][N4][N6].
  • Enveric has publicly communicated plans for IND filings and assembling clinical teams to manage trials [S1][N1].
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-27 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-10-22 | www.nasdaq.com | Enveric Biosciences Moves Lead Neuroplastogenic Candidate Closer To Clinical Testing | https://www.nasdaq.com/articles/enveric-biosciences-moves-lead-neuroplastogenic-candidate-closer-clinical-testing
  • N2 | 2026-05-15 | www.nasdaq.com | Enveric Reports $1 Mln Loss In Q1; Advances EB-003 In Preclinical Studies | https://www.nasdaq.com/articles/enveric-reports-1-mln-loss-q1-advances-eb-003-preclinical-studies
  • N3 | 2026-04-30 | www.nasdaq.com | Morning Market Movers: HCAI, FATN, ENVB, AKAN See Big Swings | https://www.nasdaq.com/articles/morning-market-movers-hcai-fatn-envb-akan-see-big-swings
  • N4 | 2026-04-20 | www.nasdaq.com | Enveric Closes $13.9 Million Private Placement To Advance Neuroplastogen Pipeline; Stock Up | https://www.nasdaq.com/articles/enveric-closes-139-million-private-placement-advance-neuroplastogen-pipeline-stock
  • N5 | 2026-03-28 | www.nasdaq.com | Enveric Biosciences to Release Investor Presentation | https://www.nasdaq.com/articles/enveric-biosciences-release-investor-presentation
  • N6 | 2026-02-19 | www.nasdaq.com | Enveric's EB-003 Assay Data Shows Dual 5-HTA Pathway Engagement; Stock Up | https://www.nasdaq.com/articles/enverics-eb-003-assay-data-shows-dual-5-hta-pathway-engagement-stock
  • N7 | 2025-09-16 | www.nasdaq.com | Enveric Biosciences Gets FDA Response On Request For Pre-IND Type B Meeting For Lead Program EB-003 | https://www.nasdaq.com/articles/enveric-biosciences-gets-fda-response-request-pre-ind-type-b-meeting-lead-program-eb-003
  • N8 | 2025-01-31 | www.nasdaq.com | Enveric Biosciences Prices Public Offering At $3.00/Shr | https://www.nasdaq.com/articles/enveric-biosciences-prices-public-offering-300-shr
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine